Skip to content
Catalyst

PapersPMID:39275290

Effects of Casein-Derived Peptide Met-Lys-Pro on Systolic and Diastolic Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.

Nutrients2024The record ↗

findings
3
compound
1
endpoints
3
no difference found
1
PMID:39275290
  1. Finding, moderate evidencelowersSystolic blood pressure
  2. Finding, moderate evidencelowersDiastolic blood pressure
  3. Finding, moderate evidenceno difference foundAdverse event occurrence (oral or enteral supplement)
Study, every finding
RCT · 3 months
Dose studied, every finding
one sachet once daily containing 100 ug Met-Lys-Pro, taken with a drink, 12 weeks
  • “SBP (ls mean ± SE) was 123.0 ± 1.4 mmHg in the MKP group and 128.1 ± 1.4 mmHg in the placebo group at Week 12, which was significantly lower in the MKP group (ANCOVA; p < 0.05).”
    Interests
    Industry funded
    Population
    Healthy Japanese adults aged 20 to 74 with high-normal or elevated blood pressure (SBP 120-139 mmHg and/or DBP 80-89 mmHg), per-protocol set, week 12 of 12 weeks, ANCOVA adjusted for baseline
  • “DBP (ls mean ± SE) was 77.4 ± 0.9 mmHg in the MKP group and 80.1 ± 0.9 mmHg in the placebo group at Week 12, which was significantly lower in the MKP group (ANCOVA; p < 0.05).”
    Interests
    Industry funded
    Population
    Healthy Japanese adults aged 20 to 74 with high-normal or elevated blood pressure (SBP 120-139 mmHg and/or DBP 80-89 mmHg), per-protocol set, week 12 of 12 weeks, ANCOVA adjusted for baseline

What did not

  • “There was no significant difference in the incidence of adverse events between the two groups (MKP group; 65.0%, placebo group; 59.3%, p > 0.1).”
    Interests
    Industry funded
    Population
    Healthy Japanese adults aged 20 to 74 with high-normal or elevated blood pressure, safety analysis set, 12 weeks

Study record

Design
randomised controlled trial
Species
human
Population
Japanese adults aged 20 to 74 years with high-normal or elevated blood pressure (SBP above 120 or DBP above 80 mmHg, below 140/90), Matsumoto, Nagano; casein hydrolysate containing 100 ug casein-derived tripeptide Met-Lys-Pro (MKP) versus dextrin placebo, parallel groups
Participants
121
Comparator
placebo
Duration
84 days
Endpoints measured
7